# Clinical Study of Chidamide Combined With Chemotherapy in Neoadjuvant Treatment of HR+/ HER2-BC

> **NCT05400993** · PHASE2 · UNKNOWN · sponsor: **Shengjing Hospital** · enrollment: 59 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **COMBINATION_PRODUCT:** Chidamide

## Key facts

- **NCT ID:** NCT05400993
- **Lead sponsor:** Shengjing Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-23
- **Primary completion:** 2023-05-23
- **Final completion:** 2024-05-23
- **Target enrollment:** 59 (ESTIMATED)
- **Last updated:** 2022-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05400993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05400993, "Clinical Study of Chidamide Combined With Chemotherapy in Neoadjuvant Treatment of HR+/ HER2-BC". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05400993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*